Andrea Banty, NP, DNP: Navigating New Developments in IBD Therapeutics - HCPLive
Recent FDA approval of guselkumab (Tremfya) for UC and other advancements in IBD treatment offer more options, prompting reevaluation of CD and UC management. Andrea Banty, NP, DNP, emphasizes the importance of aligning patient goals with treatment options, considering administration preferences and safety risks.
Reference News
Andrea Banty, NP, DNP: Navigating New Developments in IBD Therapeutics - HCPLive
Recent FDA approval of guselkumab (Tremfya) for UC and other advancements in IBD treatment offer more options, prompting reevaluation of CD and UC management. Andrea Banty, NP, DNP, emphasizes the importance of aligning patient goals with treatment options, considering administration preferences and safety risks.